A selective estrogen receptor modulator inhibits TNF-α-induced apoptosis by activating ERK1/2 signaling pathway in vascular endothelial cells

Vascular Pharmacology

Volumn 51, Issue 1, 2009, Pages 21-28

  Yu, Jing ^a   Eto, Masato ^a   Akishita, Masahiro ^a   Okabe, Tetsuro ^a   Ouchi, Yasuyoshi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Apoptosis; Endothelial cell; ERK 1 2; Selective estrogen receptor modulator; TNF

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 6 HYDROXY 2 (4 HYDROXYPHENYL) 3 [4 [2 (1 PYRROLIDINYL)ETHOXY]BENZOYL]BENZO[B]THIOPHENE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; CASPASE 3; ESTRADIOL; FULVESTRANT; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN KINASE B; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; APOPTOSIS; ARTERY ENDOTHELIUM; ARTICLE; CAROTID ARTERY; CELL DEATH; CELL PROTECTION; DNA DEGRADATION; ENDOTHELIUM CELL; ENZYME ACTIVATION; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANIMALS; APOPTOSIS; CATTLE; CELL SURVIVAL; CELLS, CULTURED; ENDOTHELIAL CELLS; ENZYME ACTIVATION; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PYRROLIDINES; SELECTIVE ESTROGEN RECEPTOR MODULATORS; THIOPHENES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 67349235288     PISSN: 15371891     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vph.2009.01.003     Document Type: Article

References (55)

1. Barrett-Connor E., Cauley J.A., Kulkarni P.M., Sashegyi A., Cox D.A., and Geiger M.J. Risk-benefit profile for raloxifene: 4-year data from the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial. J. Bone Miner. Res. 19 (2004) 1270-1275
2. Beg A.A., and Baltimore D. An essential role for NF-kappaB in preventing TNF-alpha-induced cell death. Science 274 (1996) 782-784
3. Bellosta S., Baetta R., Canavesi M., Comparato C., Granata A., Monetti M., Cairoli F., Eberini I., Puglisi L., and Corsini A. Raloxifene inhibits matrix metalloproteinases expression and activity in macrophages and smooth muscle cells. Pharmacol. Res. 56 (2007) 160-167
4. Berk B.C., Abe J.I., Min W., Surapisitchat J., and Yan C. Endothelial atheroprotective and anti-inflammatory mechanisms. Ann. N. Y. Acad. Sci. 947 (2001) 93-109
5. Bradham C.A., Qian T., Streetz K., Trautwein C., Brenner D.A., and Lemasters J.J. The mitochondrial permeability transition is required for tumor necrosis factor alpha-mediated apoptosis and cytochrome c release. Mol. Cell Biol. 18 (1998) 6353-6364
6. Campbell M., Allen W.E., Sawyer C., Vanhaesebroeck B., and Trimble E.R. Glucose-potentiated chemotaxis in human vascular smooth muscle is dependent on cross-talk between the PI3K and MAPK signaling pathways. Circ. Res. 95 (2004) 380-388
7. Chang L., and Karin M. Mammalian MAP kinase signalling cascades. Nature 410 (2001) 37-40
8. Chen G., Shen X., Yao J., Chen F., Lin X., Qiao Y., You T., Lin F., Fang X., Zou X., and Lin L. Ablation of NF-kappaB expression by small interference RNA prevents the dysfunction of human umbilical vein endothelial cells induced by high glucose. Endocrine 35 (2009) 63-74
9. Clarkson T.B. Estrogen effects on arteries vary with stage of reproductive life and extent of subclinical atherosclerosis progression. Menopause 14 (2007) 373-384
10. Colacurci N., Fornaro F., Cobellis L., De Franciscis P., Torella M., Sepe E., Arciello A., Cacciapuoti F., Paolisso G., and Manzella D. Raloxifene slows down the progression of intima-media thickness in postmenopausal women. Menopause 14 (2007) 879-884
11. Cox D.A., Sarkar S., Harper K., and Barrett-Connor E. Effect of raloxifene on the incidence of elevated low density lipoprotein (LDL) and achievement of LDL target goals in postmenopausal women. Curr. Med. Res. Opin. 7 (2004) 1049-1055
12. Delmas P.D., Bjarnason N.H., Mitlak B.H., Ravoux A.C., Shah A.S., Huster W.J., Draper M., and Christiansen C. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N. Engl. J. Med. 337 (1997) 1641-1647
13. Enari M., Sakahira H., Yokoyama H., Okawa K., Iwamatsu A., and Nagata S. A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature 391 (1998) 43-50
14. Florian M., and Magder S. Estrogen decreases TNF-alpha and oxidized LDL induced apoptosis in endothelial cells. Steroids 73 (2008) 47-58
15. Geraldes P., Sirois M.G., Bernatchez P.N., and Tanguay J.F. Estrogen regulation of endothelial and smooth muscle cell migration and proliferation: role of p38 and p42/44 mitogen-activated protein kinase. Arterioscler. Thromb. Vasc. Biol. 22 (2002) 1585-1590
16. Giri D.K., and Aggarwal B.B. Constitutive activation of NF-kappaB causes resistance to apoptosis in human cutaneous T cell lymphoma HuT-78 cells. Autocrine role of tumor necrosis factor and reactive oxygen intermediates. J. Biol. Chem. 273 (1998) 14008-14014
17. Grady D., Herrington D., Bittner V., Blumenthal R., Davidson M., Hlatky M., Hsia J., Hulley S., Herd A., Khan S., Newby L.K., Waters D., Vittinghoff E.E., Wenger N., and HERS Research Group. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 288 (2002) 49-57
18. Grady D., Ettinger B., Moscarelli E., Plouffe Jr. L., Sarkar S., Ciaccia A., and Cummings S. Safety and adverse effects associated with raloxifene: multiple outcomes of raloxifene evaluation. Obstet. Gynecol. 104 (2004) 837-844
19. Hulley S., Grady D., Bush T., Furberg C., Herrington D., Riggs B., and Vittinghoff E.E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 280 (1998) 605-613
20. Johnell O., Cauley J.A., Kulkarni P.M., Wong M., and Stock J.L. Raloxifene reduces risk of vertebral fractures and breast cancer in postmenopausal women regardless of prior hormone therapy. J. Fam. Pract. 53 (2004) 789-796
21. Kalechman Y., Longo D.L., Catane R., Shani A., Albeck M., and Sredni B. Synergistic anti-tumoral effect of paclitaxel (Taxol)+AS101 in a murine model of B16 melanoma: association with ras-dependent signal-transduction pathways. Int. J. Cancer. 86 (2000) 281-288
22. Kannel W.B., Hjortland M.C., McNamara P.M., and Gordon T. Menopause and risk of cardiovascular disease: the Framingham study. Ann. Intern. Med. 85 (1976) 447-452
23. Kobayashi T., Okamoto K., Kobata T., Hasunuma T., Sumida T., and Nishioka K. Tumor necrosis factor alpha regulation of the FAS-mediated apoptosis-signaling pathway in synovial cells. Arthritis. Rheum. 42 (1999) 519-526
24. Koga M., Hirano K., Hirano M., Nishimura J., Nakano H., and Kanaide H. Akt plays a central role in the anti-apoptotic effect of estrogen in endothelial cells. Biochem. Biophys. Res. Commun. 324 (2004) 321-325
25. Kuipper G.G., Carlsson B., Grandien K., Enmark E., Häggblad J., Nisson S., and Gustafsson J.A. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology 138 (1997) 863-870
26. Levy N., Tatomer D., Herber C.B., Zhao X., Tang H., Sargeant T., Ball L.J., Summers J., Speed T.P., and Leitman D.C. Differential regulation of native estrogen receptor regulatory elements by estradiol, tamoxifen, and raloxifene. Mol. Endocrinol, 22 (2008) 287-303
27. Lieu C.H., Liu C.C., Yu T.H., Chen K.D., Chang Y.N., and Lai Y.K. Role of mitogen-activated protein kinase in taxol-induced apoptosis in human leukemic U937 cells. Cell. Growth. Differ. 9 (1998) 767-776
28. Li Y., and Tabas I. The inflammatory cytokine response of cholesterol-enriched macrophages is dampened by stimulated pinocytosis. J. Leukoc. Biol. 81 (2007) 483-491
29. Matsuzaki H., Tamatani M., Mitsuda N., Namikawa K., Kiyama H., Miyake S., and Tohyama M. Activation of Akt kinase inhibits apoptosis and changes in Bcl-2 and Bax expression induced by nitric oxide in primary hippocampal neurons. J. Neurochem. 73 (1999) 2037-2046
30. Maugeri D., Mamazza C., Lo Giudice F., Puglisi N., Muscoso E.G., Rizzotto M., Testaì M., Bennati E., Lentini A., and Panebianco P. Interleukin-18 (IL-18) and matrix metalloproteinase-9 (MMP-9) in post-menopausal osteoporosis. Arch. Gerontol. Geriatr. 40 (2005) 299-305
31. Moon S.K., Kim H.M., Lee Y.C., and Kim C.H. Disialoganglioside (GD3) synthase gene expression suppresses vascular smooth muscle cell responses via the inhibition of ERK1/2 phosphorylation, cell cycle progression, and matrix metalloproteinase-9 expression. J. Biol. Chem. 279 (2004) 33063-33070
32. Nettles K.W., and Greene G.L. Ligand control of coregulator recruitment to nuclear receptors. Annu. Rev. Physiol. 67 (2005) 309-333
33. Nguyen T.T., Tran E., Nguyen T.H., Do P.T., Huynh T.H., and Huynh H. The role of activated MEK-ERK pathway in quercetin-induced growth inhibition and apoptosis in A549 lung cancer cells. Carcinogenesis 25 (2004) 647-659
34. Nicholson D.W., Ali A., Thornberry N.A., Vaillancourt J.P., Ding C.K., Gallant M., Gareau Y., Griffin P.R., Labelle M., Lazebnik Y.A., Munday N.A., Raju S.M., Smulson M.E., Yamin T.T., Yu V.L., and Miller D.K. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 376 (1995) 37-43
35. Rath P.C., and Aggarwal B.B. TNF-induced signaling in apoptosis. J. Clin. Immunol. 19 (1999) 350-364
36. Ross R. Atherosclerosis - an inflammatory disease. N. Engl. J. Med. 340 (1999) 115-126
37. Rossouw J.E., Anderson G.L., Prentice R.L., LaCroix A.Z., Kooperberg C., Stefanick M.L., Jackson R.D., Beresford S.A., Howard B.V., Johnson K.C., Kotchen J.M., Ockene J., and Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 288 (2002) 321-333
38. Savolainen-Peltonen H., Luoto N.M., Kangas L., and Häyry P. Selective estrogen receptor modulators prevent neointima formation after vascular injury. Mol. Cell. Endocrinol. 227 (2004) 9-20
39. Sbarouni E., Flevari P., Kroupis C., Kyriakides Z.S., Koniavitou K., and Kremastinos D.T. The effects of raloxifene and simvastatin on plasma lipids and endothelium. Cardiovasc. Drugs Ther. 17 (2003) 319-323
40. Secchiero P., Gonelli A., Carnevale E., Milani D., Pandolfi A., Zella D., and Zauli G. TRAIL promotes the survival and proliferation of primary human vascular endothelial cells by activating the Akt and ERK pathways. Circulation 107 (2003) 2250-2256
41. Sporn M.B., Dowsett S.A., Mershon J., and Bryant H.U. Role of raloxifene in breast cancer prevention in postmenopausal women: clinical evidence and potential mechanisms of action. Clin. Ther. 26 (2004) 830-840
42. Surapisitchat J., Hoefen R.J., Pi X., Yoshizumi M., Yan C., and Berk B.C. Fluid shear stress inhibits TNF-alpha activation of JNK but not ERK1/2 or p38 in human umbilical vein endothelial cells: inhibitory crosstalk among MAPK family members. Proc. Natl. Acad. Sci. 98 (2001) 6476-6481
43. Takahashi K., Ohmichi M., Yoshida M., Hisamoto K., Mabuchi S., Arimoto-Ishida E., Mori A., Tsutsumi S., Tasaka K., Murata Y., and Kurachi H. Both estrogen and raloxifene cause G1 arrest of vascular smooth muscle cells. J. Endocrinol. 178 (2003) 319-329
44. Uchiyama T., Engelman R.M., Maulik N., and Das D.K. Role of Akt signaling in mitochondrial survival pathway triggered by hypoxic preconditioning. Circulation 22 (2004) 3042-3049
45. Van Antwerp D.J., Martin S.J., Kafri T., Green D.R., and Verma I.M. Suppression of TNF-alpha-induced apoptosis by NF-kB. Science 274 (1996) 787-789
46. Wada T., and Penninger J.M. Mitogen-activated protein kinases in apoptosis regulation. Oncogene 23 (2004) 2838-2849
47. Wang C.Y., Mayo M.W., and Baldwin Jr. A.S. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NFkappaB. Science 274 (1996) 784-787
48. Wang C.Y., Cusack J.C., Liu R., and Baldwin Jr. A.S. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat. Med. 5 (1999) 412-417
49. Wang C.Y., Guttridge D.C., Mayo M.W., and Baldwin Jr. A.S. NF-kappaB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis. Mol. Cell. Biol. 19 (1999) 5923-5929
50. Weatherman R.V., Clegg N.J., and Scanlan T.S. Differential SERM activation of the estrogen receptors (ER alpha and ER beta) at AP-1 sites. Chem. Biol. 8 (2001) 427-436
51. Wijarayatne A.L., Nagel S.C., Paige L.A., Christensen D.J., Norris J.D., Fowlkes D.W., and McDonnell D.P. Comparative analyses of mechanistic differences among antiestrogens. Endocrinology 140 (1999) 5828-5840
52. Xia Z., Dickens M., Raingeaud J., Davis R.J., and Greenberg M.E. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 270 (1995) 1326-1331
53. Xiang Q.L., Chen Y., Lin G.P., Tan Z., and Wang T.H. Effects of selective estrogen receptor modulator raloxifene plus 17-beta estradiol in aorta and mammary gland of female experimental atherosclerosis rabbits and possible involvement of ERK signal transduction pathway. Chin. J. Physiol. 49 (2006) 132-140
54. Yu J., Eto M., Akishita M., Kaneko A., Ouchi Y., and Okabe T. Signaling pathway of nitric oxide production induced by ginsenoside Rb1 in human aortic endothelial cells: a possible involvement of androgen receptors. Biochem. Biophys. Res. Commun. 353 (2007) 764-769
55. Yu J., Eto M., Kozaki K., Akishita M., Okabe T., and Ouchi Y. Raloxifene analogue LY117018 suppresses oxidative stress-induced endothelial cell apoptosis through activation of ERK1/2 signaling pathway. Eur. J. Pharmacol. 589 (2008) 32-36